Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€20.63

€20.63

0.220%
0.045
0.220%
€40.54
 
09:03 / Tradegate WKN: 852009 / Symbol: PFE / Name: Pfizer / Stock / Pharmaceuticals / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction

Pfizer Inc. Stock

The Pfizer Inc. stock is trending slightly upwards today, with an increase of €0.045 (0.220%) compared to yesterday's price.
With 18 Buy predictions and only 1 Sell predictions the community sentiment for the stock is positive.
With a target price of 40 € there is a hugely positive potential of 93.89% for Pfizer Inc. compared to the current price of 20.63 €.
Our community identified positive and negative aspects for Pfizer Inc. stock for the coming years. 15 users see the criterium "Worthwhile Investment for the next years" as a plus for the Pfizer Inc. stock. On the other hand our users think that "Conscious of the environment" could be a problem in the future.

Pros and Cons of Pfizer Inc. in the next few years

Pros
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Cons
?
S********** s********
?
B****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Pfizer Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Pfizer Inc. 0.220% -0.819% -0.339% -21.221% -18.861% -58.953% -25.697%
Elanco Animal Health Inc. 1.870% 5.133% 1.779% -9.964% 5.005% -35.252% -36.513%
Johnson & Johnson -0.080% -0.887% -4.985% -4.985% -6.802% -23.645% 3.580%
Biogen Inc. 0.660% -1.113% -6.696% -50.785% -25.998% -45.238% -55.257%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2024-08-01

When diving into the financials of Pfizer Inc. (PFE), a major player within the pharmaceuticals industry, a mixed picture starts to emerge. On the one hand, the company boasts a solid revenue stream and demonstrates a commendable operating margin, creating an impression of profitability. On the other hand, several warning signs appear in the form of declining growth metrics and concerns over income stability. Now, let’s break down the analysis into pros and cons to provide a comprehensive view.

Strong Revenue Performance: Pfizer reported a total revenue of approximately $54.89 billion over the trailing twelve months. This figure suggests that the company has maintained a robust sales figure, driven largely by their pharmaceutical portfolio, including well-known products and newly developed vaccines.

Healthy Operating Margins: The operating margin, standing at around 31.63%, illustrates the company's efficiency in turning sales into profit. This is relatively strong for the pharmaceutical sector, indicating that Pfizer is effectively managing its operating expenses relative to its revenue.

Comments

Pfizer Inc. (NYSE: PFE) had its "buy" rating re-affirmed by analysts at Guggenheim.
Ratings data for PFE provided by MarketBeat
Show more

Pfizer Inc. (NYSE: PFE) had its "buy" rating re-affirmed by analysts at Guggenheim.
Ratings data for PFE provided by MarketBeat
Show more

Prediction Buy
Perf. (%) -17.75%
Target price 31.984
Change
Ends at 10.02.26

Pfizer Inc. (NYSE: PFE) had its "buy" rating re-affirmed by analysts at Guggenheim. They now have a $33.00 price target on the stock.
Ratings data for PFE provided by MarketBeat
Show more

News

Pfizer Announces Positive Topline Phase 3 Results for HYMPAVZI™ in Hemophilia A or B with Inhibitors
Pfizer Announces Positive Topline Phase 3 Results for HYMPAVZI™ in Hemophilia A or B with Inhibitors


Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 BASIS study (NCT03938792) evaluating HYMPAVZI™ (marstacimab) for adults and adolescents living with hemophilia A or

Pfizer Declares Third-Quarter 2025 Dividend
Pfizer Declares Third-Quarter 2025 Dividend


Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 third-quarter 2025 dividend on the company’s common stock, payable September 2, 2025, to holders of the Common

Pfizer Invites Public to View and Listen to Webcast of August 5 Conference Call with Analysts
Pfizer Invites Public to View and Listen to Webcast of August 5 Conference Call with Analysts


Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EDT on Tuesday, August 5, 2025. The